In a twist on the traditional smoking cessation model, GlaxoSmithKline is pairing with 2morrow's SmartQuit app to supply patches to smokers who have already completed the app plan.
Australia's Adherium Group announced clearance to sell its SmartTurbo and SmartTouch "smart inhaler" devices in Canada. They improve adherence by tracking usage and sending reminders.
Already a growing presence in bioelectronics, GlaxoSmithKline is taking its efforts to the next level with plans to roll out implantable devices that send electric pulses to treat certain chronic diseases.
A drumbeat of policy steps and guidance from China so far this year has made it more than clear the country intends to buy, make and prescribe drugs in drastically new ways and at lower costs--and that should ring a bell for earlier insight along those lines by GlaxoSmithKline CEO Andrew Witty.
GlaxoSmithKline is cutting ties with Five Prime Therapeutics' in-development cancer therapy, backing out in the middle of a mesothelioma trial.
Novartis has stopped a Phase III trial of Genmab's Arzerra in pemphigus vulgaris patients. The decision, which comes 7 months after Novartis agreed to buy the rights to Arzerra in autoimmune indications from GlaxoSmithKline, will result in a focusing of attention on the testing of the monoclonal antibody as a treatment for relapsing multiple sclerosis.
GlaxoSmithKline has renewed its contract with business process management company WNS. The extension of the relationship means GSK will continue to rely on WNS for research and analytics services until at least December 2020.
The U.K. rolled out its meningitis B vaccination program for babies in September, but a petition demanding that it be expanded for all children quickly gathered steam. The Department of Health rejected the petition on Wednesday, saying that offering the jab to all children would not be cost-effective.
A vaccine developed in collaboration between GlaxoSmithKline and the U.S. Army failed to protect subjects in an early trial against the world's most prevalent malaria parasite. Researchers will press forward, however, saying the knowledge gained may assist future development.
GlaxoSmithKline is casting about for a new CEO. Amid shareholder pressure for a breakup or shake-up or both, the company reportedly has asked its headhunting firm to put together a short list of candidates to replace current chief Andrew Witty.